Monaco Asset Management SAM Purchases Shares of 184,937 BioMarin Pharmaceutical Inc. $BMRN

Monaco Asset Management SAM purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 184,937 shares of the biotechnology company’s stock, valued at approximately $10,582,000. BioMarin Pharmaceutical makes up about 0.8% of Monaco Asset Management SAM’s portfolio, making the stock its 8th biggest holding.

Other hedge funds have also recently made changes to their positions in the company. Swedbank AB lifted its stake in BioMarin Pharmaceutical by 70.6% in the fourth quarter. Swedbank AB now owns 796,737 shares of the biotechnology company’s stock worth $47,350,000 after purchasing an additional 329,794 shares during the last quarter. LSV Asset Management grew its stake in shares of BioMarin Pharmaceutical by 4.3% during the fourth quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company’s stock valued at $52,429,000 after buying an additional 36,700 shares during the last quarter. C WorldWide Group Holding A S grew its stake in shares of BioMarin Pharmaceutical by 12.6% during the fourth quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company’s stock valued at $15,918,000 after buying an additional 30,000 shares during the last quarter. KBC Group NV grew its stake in shares of BioMarin Pharmaceutical by 10.0% during the fourth quarter. KBC Group NV now owns 168,779 shares of the biotechnology company’s stock valued at $10,031,000 after buying an additional 15,362 shares during the last quarter. Finally, Horizon Investments LLC increased its holdings in shares of BioMarin Pharmaceutical by 22.3% in the fourth quarter. Horizon Investments LLC now owns 99,681 shares of the biotechnology company’s stock worth $5,924,000 after buying an additional 18,143 shares during the period. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $67.36 on Monday. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $70.98. The stock has a market capitalization of $13.04 billion, a P/E ratio of 182.05, a P/E/G ratio of 0.47 and a beta of 0.24. The company’s 50-day moving average is $59.56 and its 200 day moving average is $57.51. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.25. The company had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The firm’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, sell-side analysts expect that BioMarin Pharmaceutical Inc. will post 4.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BMRN. Bank of America lowered their target price on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Citigroup lifted their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. HC Wainwright boosted their price objective on BioMarin Pharmaceutical from $50.00 to $60.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Sanford C. Bernstein dropped their price objective on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Finally, Oppenheimer raised their target price on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $88.00.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.